1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comprehensive and collaborative workflow to establish customized endpoints and biomarkers for immunotherapy trials
    Meeting Abstract

    Vidal, E. H.; Mcavoy, D.; Vallone, A.; Thomsen, M.; Maslak, P.; Harris, A.; Oved, J.; Hosszu, K.; Boelens, J. J.
    Cytotherapy (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3, A phase III randomized controlled trial (RCT)
    Meeting Abstract

    Giralt, S.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Progression-free survival of daratumumab vs bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: TAURUS chart review study
    Meeting Abstract

    Gordan, L.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma: A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Happ, L. P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Early mortality in multiple myeloma- A SEER data analysis
    Meeting Abstract

    Wei, J.; Shastri, A.; Sica, R. A.; Mantzaris, I.; Kornblum, N.; Shah, U.; Janakiram, M.; Gritsman, K.; Verma, A.; Goldfinger, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M. S.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma (MM) in a hospital setting in the US: Premier Healthcare Database study
    Meeting Abstract

    Tan, C. R.; Chinaeke, E.; Kim, N.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save